natgillin/translations-raw huggingface dataset:
The adjusted mean change in body weight from baseline at 104 weeks was -2.6 kg for Eperzan (N = 184) and +1.4 kg for insulin glargine (N = 104). 
Korigirana povprečna sprememba telesne mase v primerjavi z izhodiščem je bila po 104 tednih -2,6 kg za zdravilo Eperzan (N = 184) in +1,4 kg insulin glargin (N = 104).
Dispose of the pen as instructed by your doctor, pharmacist or nurse. 
Peresnik zavrzite, kot vam je naročil zdravnik, farmacevt ali medicinska sestra.
In clinical trials, acute pancreatitis has been reported in association with Eperzan (see section 4.8). 
kliničnih preskušanjih so poročali o akutnem pankreatitisu v povezavi z zdravilom Eperzan (glejte poglavje
Treatment with Eperzan did not meet the pre-specified noninferiority margin (0.3%) against pioglitazone for HbA1c. 
Zdravljenje z zdravilom Eperzan v primerjavi s pioglitazonom ni doseglo vnaprej opredeljene meje neinferiornosti (0,3 %) za HbA1c.
INSTRUCTIONS FOR USE 
NAVODILO ZA UPORABO
You and your doctor should decide whether you will use Eperzan or breast-feed. 
Skupaj z zdravnikom se morate odločiti, ali boste uporabljali zdravilo
Eperzan has no or negligible influence on the ability to drive or use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Zdravilo Eperzan nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Eperzan 30 mg SC weekly was compared to placebo in patients inadequately controlled on pioglitazone 30 mg daily (with or without metformin 1,500 mg daily). 
Zdravilo Eperzan 30 mg subkutano na teden so primerjali s placebom pri bolnikih, neustrezno urejenih z ≥ 30 mg pioglitazona na dan (z ≥ 1.500 mg metformina na dan ali brez njega).
Following SC administration of a single 30 mg dose to subjects with type 2 diabetes, maximum concentrations were reached 3 to 5 days post dose with mean peak albiglutide concentration (Cmax) of 1.74 mcg/ml and mean area under the time-concentration curve (AUC) of 465 mcg.h/ml. 
Absorpcija Po subkutani uporabi posamičnega odmerka 30 mg pri preiskovancih s sladkorno boleznijo tipa 2 je bila največja koncentracija dosežena od 3 do 5 dni po odmerku; povprečna najvišja koncentracija albiglutida (Cmax) je bila 1,74 µg/ml in povprečna površina pod krivuljo koncentracije po času (AUC) 465 µg.h/ml.
IMPORTANT: There are two needle caps, an outer and inner needle cap. 7b While holding the pen in the air, remove outer needle cap (Figure Q) and inner needle cap (Figure R). 
7b Medtem ko držite peresnik v zraku, snemite zunanji pokrovček igle (Slika Q) in notranji pokrovček igle (Slika R).
No dose adjustment is necessary for patients with mild and moderate renal impairment (eGFR 60 to 89 and 30 to 59 ml/min/1.73m2, respectively) (see sections 4.4, 4.8, 5.1, 5.2). 
Bolnikom z blago in zmerno okvaro ledvic (blaga: eGFR od 60 do 89 ml/min/1,73 m2; zmerna: eGFR od 30 do 59 ml/min/1,73 m2) odmerka ni treba prilagoditi (glejte poglavja 4.4, 4.8, 5.1 in 5.2).
Use Eperzan for as long as your doctor recommends. 
Če ste prenehali uporabljati zdravilo Eperzan Zdravilo Eperzan uporabljajte toliko časa, kot vam svetuje zdravnik.
Eperzan 30 mg/50 mg Weekly 
Eperzan 30 mg/50 mg na teden
No carcinogenicity studies have been performed with albiglutide due to immunogenicity in rodents. 
Zaradi imunogenosti pri glodalcih z albiglutidom niso izvedli študij kancerogenosti.
The white injection button will also pop out from the bottom of the pen. 
Iz spodnjega dela peresnika bo pogledal beli gumb za injiciranje.
Pen Body 
Telo peresnika
Sitagliptin was dosed according to creatinine clearance estimated by Cockcroft-Gault formula (100 mg daily in mild, 50 mg daily in moderate, and 25 mg daily in severe renal impairment) The primary endpoint was change in HbA1c from baseline at 26 weeks. 
Sitagliptin so odmerjali glede na očistek kreatinina, ocenjen po Cockcroft-Gaultovi formuli (100 mg na dan pri blagi, 50 mg na dan pri zmerni in 25 mg na dan pri hudi okvari ledvic).
You should not take acarbose if you suffer from bowel obstruction. 
Če imate zaporo črevesa, ne smete jemati akarboze.
What Eperzan contains - The active substance is albiglutide. 
Zdravilo Eperzan vsebuje kot zdravilno učinkovino albiglutid.
Compared to placebo, treatment with Eperzan 30 mg and 50 mg SC weekly resulted in statistically significant reductions in HbA1c from baseline at Week 52. 
Zdravljenje z zdravilom Eperzan 30 mg in 50 mg subkutano tedensko je v primerjavi s placebom do 52. tedna statistično značilno znižalo HbA1c v primerjavi z izhodiščem.
Proportion Achieving HbA1c <7% 
HbA1c < 7 %
In reproductive toxicology studies with albiglutide in mice, there were no effects on mating or fertility at doses up to 50 mg/kg/day (at low multiple of clinical exposure). 
V študijah reproduktivne toksičnosti albiglutida pri miših v odmerkih do 50 mg/kg/dan (to je nizek večkratnik klinične izpostavljenosti) niso ugotovili vpliva na parjenje ali plodnost.
The primary endpoint was change in HbA1c from baseline at 2 years compared to placebo. 
Primarni opazovani dogodek je bila sprememba HbA1c od izhodišča po 2 letih v primerjavi s placebom.
METHOD AND ROUTE(S) OF ADMINISTRATION Read package leaflet. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Preberite navodilo za uporabo.
The pen injector contains powder and water which you need to mix before you can use it. After section 6 of this leaflet there are Instructions For Use giving you step-by-step instructions on how to mix your medicine and how to inject it. 
Poglavju 6 tega navodila sledijo Navodila za uporabo, v katerih je korak za korakom pojasnjeno, kako zmešate zdravilo in kako ga injicirate.
The median daily dose of insulin glargine used prior to hyperglycaemic rescue was 10 units (range 2 to 40 units) at study start and 30 units (range 3 to 230 units) at Week 52. 
Mediani dnevni odmerek insulina glargina, uporabljenega pred reševanjem hiperglikemije, je bil 10 enot (razpon: od 2 do 40
Carton of 4 single-dose pens and 4 pen needles. 
Škatla s 4 peresniki z enkratnim odmerkom in 4 iglami za peresnik.
If you are breast-feeding you must check with your doctor before you use Eperzan. 
Če dojite, se morate pred uporabo zdravila Eperzan posvetovati z zdravnikom.
The medicine can be stored at room temperature (less than 30C) for no more than a total of 4 weeks before use. 
To zdravilo lahko shranjujete na sobni temperaturi (manj kot 30 °C), vendar ne več kot skupaj 4 tedne pred uporabo.
Eperzan is intended for patient self-administration as a subcutaneous injection in the abdomen, thigh or upper arm region. 
Zdravilo Eperzan je namenjeno za bolnikovo samoinjiciranje, v obliki subkutane injekcije v trebuh, stegno ali nadlaket.
- on its own if your blood sugar is not properly controlled by diet and exercise alone, and you can't take metformin (another diabetes medicine) 
Zdravilo Eperzan se uporablja kot pomoč za uravnavanje krvnega sladkorja, in sicer: - kot samostojno zdravljenje, če krvnega sladkorja nimate ustrezno urejenega samo z dieto in telesno dejavnostjo ter ne morete jemati metformina (drugo zdravilo za zdravljenje sladkorne bolezni) ali
Twist clear cartridge several times in the direction of the arrow until you feel/hear the pen “click” into place. 
Večkrat zasučite prozorni vložek v smeri puščice, dokler ne začutite ali zaslišite, da peresnik "klikne".
The adjusted mean change in body weight from baseline at 52 weeks was -1.0 kg for Eperzan (N = 122) and +1.7 kg for insulin lispro (N = 141). 
Korigirana povprečna sprememba telesne mase v primerjavi z izhodiščem je bila po 52 tednih -1,0 kg za zdravilo Eperzan (N = 122) in +1,7 kg insulin lispro (N = 141).
Eperzan should not be used while you're pregnant. 
Med nosečnostjo zdravila Eperzan ne smete uporabljati.
Decreased body weight in offspring was observed in mice treated with albiglutide during gestation and lactation (see section 5.3). 
Pri mladičih miši, ki so med gestacijo in laktacijo prejemale albiglutid, so opažali manjšo telesno maso (glejte poglavje 5.3).
• raised and itchy rashes, 
• izbočene in srbeče izpuščaje,
DO NOT turn the cartridge to [3] (Step 6b) before attaching the needle (Step 5). 
NE OBRNITE vložka na [3] (6b.
You must wait 30 minutes for the medicine to dissolve before continuing. 
Preden nadaljujete, morate počakati 30 minut, da se zdravilo raztopi.
How to take Eperzan 
Kako jemati zdravilo Eperzan
You must wait 15 minutes for the medicine to dissolve before continuing. 
Preden nadaljujete, morate počakati 15 minut, da se zdravilo raztopi.
6a With needle pointing up, gently tap the clear cartridge 2-3 times to bring large air bubbles to the top (Figure N). 
6. korak Odstranite zrak iz vložka 6a Medtem, ko je igla obrnjena navzgor, 2-krat ali 3-krat rahlo potrkajte po prozornem vložku, da se bodo veliki zračni mehurčki dvignili na vrh (Slika N).
Dehydration, sometimes leading to renal impairment and acute renal failure, has been reported in patients treated with albiglutide and has occurred in patients without gastrointestinal side effects. 
Pri bolnikih, ki so se zdravili z albiglutidom, so poročali o dehidraciji, ki se je pojavila pri bolnikih brez gastrointestinalnih neželenih učinkov, in včasih vodi v ovaro ledvic ali akutno ledvično okvaro.
For shelf life of the reconstituted product, see section 6.3. 
Za rok uporabnosti pripravljenega zdravila glejte poglavje 6.3.
Sodium content This medicine contains less than 1 mmol sodium (23 mg) per 0.5 ml dose, so is essentially ‘sodium free'. 
Zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na 0,5-ml odmerek; to pomeni, da je praktično "brez natrija".
The efficacy of Eperzan was evaluated in a 52 week, randomised, open-label, multicentre noninferiority study (n = 563). 
Učinkovitost zdravila Eperzan so ocenili v 52-tedenski randomizirani, odprti multicentrični študiji neinferiornosti (n = 563).
Change at Week 26b Difference from lispro insulinb (95% CI) 
Sprememba po 26 tednihb Razlika od insulina lisprob (95 % IZ)
Glimepiride 2 to 4 mg daily + Metformin 1,500 mgd aily 
Glimepirid 2 do 4 mg na dan + metformin ≥ 1.500 mg na dan
There are no or limited amount of data from the use of Eperzan in pregnant women. 
O uporabi zdravila Eperzan pri nosečnicah je podatkov malo ali jih ni.
Results of an active-controlled trial of Eperzan 30 mg SC weekly (with uptitration to 50 mg weekly) versus liraglutide 1.8 mg daily at 32 weeksa 
Rezultati z aktivno učinkovino kontroliranega preskušanja zdravila Eperzan 30 mg subkutano na teden (z zvišanjem na 50 mg na teden) v primerjavi z 1,8 mg liraglutida na dan po 32 tedniha Eperzan 30 mg/50 mg na teden
The incidence of pancreatitis (adjudicated as likely to be related to therapy) in the clinical studies was 0.3% for Eperzan compared to 0% for placebo and 0.1% for comparators (i.e. liraglutide, pioglitazone, glimepiride, sitagliptin, and insulin glargine) with or without additional background antidiabetic therapy (e.g. metformin). 
Incidenca pankreatitisa (po presoji ocenjenega kot verjetno povezanega z zdravljenjem) je bila v kliničnih študijah 0,3 % za zdravilo Eperzan, 0 % za placebo in 0,1 % za primerjalna zdravila (tj. liraglutid,
Pens are supplied in packs of 4 pens and 4 needles and multipacks comprising 3 packs, each containing 4 pens and 4 needles. 
Peresniki so na voljo v pakiranjih s 4 peresniki in 4 iglami ter v skupnih pakiranjih (3 pakiranja s 4 peresniki in 4 iglami za peresnike).
On background therapy of metformin 1,500 mg daily (with or without sulphonylurea), Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly) was compared to insulin glargine (started at 10 units and titrated weekly per prescribing information). 
Na podlagi osnovnega zdravljenja s ≥ 1.500 mg metformina na dan (s sulfonilsečnino ali brez nje) so zdravilo Eperzan 30 mg subkutano na teden (s fakultativnim zvišanjem na 50 mg na teden) primerjali z insulinom glarginom (uvedenim z odmerkom 10 enot in titriranim tedensko v skladu z informacijami za predpisovanje).
Eperzan is supplied as a pen for self injection. 
Zdravilo Eperzan je na voljo kot peresnik za samoinjiciranje.
PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection Multipack:12 pens (3 cartons of 4 pens/4 needles) Do not sell separately 
FARMACEVTSKA OBLIKA IN VSEBINA Prašek in vehikel za raztopino za injiciranje Skupno pakiranje: 12 peresnikov (3 škatle s 4 peresniki/4 iglami)
Placebo + Pioglitazone 30 mg daily (+/- Metformin 1,500 mg daily) 
Placebo + pioglitazon ≥ 30 mg na dan (+/- metformin ≥ 1.500 mg na dan)
Eperzan 30 mg powder and solvent for solution for injection albiglutide 
Eperzan 30 mg prašek in vehikel za raztopino za injiciranje albiglutid
Eperzan 50 mg powder and solvent for solution for injection albiglutide 
Eperzan 50 mg prašek in vehikel za raztopino za injiciranje albiglutid
Albiglutide slowed gastric emptying compared with placebo for both solids and liquids when 100 mg was administered as a single dose in healthy subjects (see section 5.1). 
Enkraten odmerek 100 mg albiglutida je pri zdravih prostovoljcih v primerjavi s placebom upočasnil želodčno praznjenje trdnih in tekočih snovi (glejte poglavje 5.1).
Results at 104 weeks in a placebo-controlled study comparing Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly) to sitagliptin 100 mg daily and glimepiride 2 to 4 mg daily as add-on therapy in patients inadequately controlled on metformin >1,500 mg daily 
Rezultati (po 104 tednih) s placebom kontrolirane študije, ki je primerjala 30 mg zdravila Eperzan na teden subkutano (s fakultativnim zvišanjem na 50 mg na teden) s 100 mg sitagliptina na dan in 2 do 4 mg glimepirida na dan kot dodatka zdravljenju bolnikov, neustrezno urejenih na metforminu > 1.500 mg na dan
The primary endpoint was change in HbA1c from baseline at 52 weeks compared to placebo. 
Primarni opazovani dogodek je bila sprememba HbA1c od izhodišča po 52 tednih v primerjavi s placebom.
On background therapy of insulin glargine (started at 10 units and titrated to  20 units per day), Eperzan 30 mg SC once weekly (with uptitration to 50 mg if inadequately controlled after Week 8) was compared to prandial insulin lispro (administered daily at mealtimes, started according to standard of care and titrated to effect). 
Na podlagi osnovnega zdravljenja z insulinom glarginom (uvedenim z odmerkom 10 enot in titriranim do ≥ 20 enot na dan) so zdravilo Eperzan 30 mg subkutano enkrat na teden (z zvišanjem na 50 mg, če bolezen po 8. tednu ni bila ustrezno urejena) primerjali s prandialnim insulinom lispro (uporabljanim vsak dan ob obrokih, uvedenim v skladu s standardno oskrbo in titriranim do učinka).
In addition no clinically relevant effects on luteinizing hormone, follicle-stimulating hormone, or progesterone were observed when albiglutide and a combination oral contraceptive were co-administered. 
Poleg tega med sočasno uporabo albiglutida in kombiniranih peroralnih kontraceptivov niso ugotovili klinično pomembnih vplivov na luteinizirajoči hormon, folikle stimulirajoči hormon ali progesteron.
Active-controlled study versus insulin glargine as add-on to metformin  sulphonylurea The efficacy of Eperzan was evaluated in a 3-year, randomised (2:1), open-label, insulin glargine-controlled noninferiority study (n = 735). 
Učinkovitost zdravila Eperzan so ocenili v 3-letni randomizirani (2:1), odprti, z insulinom glarginom kontrolirani študiji neinferiornosti (n = 735).
Glucose control 
Uravnavanje glukoze
Results at 52 weeks in a placebo-controlled study comparing Eperzan 30 mg SC weekly as add-on therapy in patients inadequately controlled on pioglitazone >30 mg daily  metformin >1,500 mg daily 
Rezultati (po 52 tednih) s placebom kontrolirane študije, ki je primerjala 30 mg zdravila Eperzan na teden subkutano kot dodatka zdravljenju bolnikov, neustrezno urejenih na pioglitazonu > 30 mg na dan ± metforminu > 1.500 mg na dan
If you use too much Eperzan, contact a doctor or pharmacist for advice. 
Če ste uporabili večji odmerek zdravila Eperzan, kot bi smeli Če ste uporabili preveč zdravila Eperzan, se posvetujte z zdravnikom ali farmacevtom.
Thyroid C-cell tumours were observed in 2 year rodent carcinogenicity studies with other GLP-1 receptor agonists. 
V 2-letnih študijah kancerogenosti drugih agonistov receptorjev GLP-1 so opažali tumorje ščitničnih celic C. V študijah teh drugih zdravil pri glodalcih je bila s hiperplazijo ščitničnih celic C in tumorji povezana zvišana koncentracija kalcitonina v serumu.
Placebo Metformin 1,500 mg daily 
Placebo + metformin ≥ 1.500 mg na dan
ATTACHING NEEDLE, REMOVING AIR FROM CARTRIDGE, AND PREPARING PEN FOR INJECTION (STEPS 5-7) 
ODSTRANJEVANJE POKROVČKOV IGLE IN INJICIRANJE ZDRAVILA (7.
DO NOT attach by screwing the needle on 
NE NAMESTITE igle s privijanjem
Body weight has no clinically relevant effect on albiglutide AUC over the range 44 to 158 kg. A 20% increase in body weight resulted in an approximate 18.5% increase in clearance. 
Telesna masa v razponu od 44 do 158 kg ni klinično pomembno vplivala na AUC albiglutida.
You inject Eperzan under your skin in your stomach area, upper leg (thigh) or in the back of your upper arm. You can inject the same area of your body each week, but don't inject in exactly the same place every time. 
Zdravilo Eperzan si injicirate pod kožo na področje trebuha, zgornjega dela noge (stegna) ali zadnje strani zgornjega dela roke (nadlakta).
anhydrous (see section 2 under ‘Sodium content'), trehalose dihydrate, mannitol, polysorbate 80. 
- Pomožne snovi so: natrijev dihidrogenfosfat monohidrat in brezvodni natrijev hidrogenfosfat (glejte poglavje 2 pod naslovom "Vsebnost natrija"), trehaloza-dihidrat, manitol, polisorbat 80.
On background therapy of metformin 1,500 mg daily plus glimepiride 4 mg daily, Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly after a minimum of 4 weeks) was compared to placebo or pioglitazone 30 mg daily (with optional titration to 45 mg/day). 
Na podlagi osnovnega zdravljenja s ≥ 1.500 mg metformina na dan + 4 mg glimepirida na dan so 30 mg zdravila Eperzan subkutano na teden (s fakultativnim zvišanjem na 50 mg na teden po najmanj 4 tednih) primerjali s placebom ali 30 mg pioglitazona na dan (s fakultativnim titriranjem na 45 mg na dan).
Treatment with Eperzan resulted in statistically significant reductions in HbA1c from baseline at Week 26 compared to sitagliptin. 
Zdravljenje z zdravilom Eperzan je v primerjavi s sitagliptinom do 26. tedna statistično značilno znižalo HbA1c v primerjavi z izhodiščem.
-2.6 (-3.2, -2.0) c a Intent to treat population - last observation carried forward b Adjusted mean c P<0.05 for treatment difference 
-2,6 (-3,2, -2,0) c a Populacija z-namenom-zdravljenja - prenos zadnjega opažanja b Korigirano povprečje c p < 0,05 za razliko med zdravljenji
When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance. 
Pri bolnikih, za katere uporaba metformina zaradi kontraindikacij ali intolerance ni primerna, samo z dieto in telesno dejavnostjo pa glikemija ni ustrezno urejena.
• Throw away the pen if leaking or jammed. 
• Če peresnik pušča ali se zatakne, ga zavrzite.
At 52 weeks, treatment with Eperzan resulted in statistically significant reductions from baseline in HbA1c compared to placebo. 
tednih je zdravljenje z zdravilom Eperzan v primerjavi s placebom statistično značilno znižalo HbA1c v primerjavi z izhodiščem.
Each pen delivers a single 30 mg or 50 mg dose of Eperzan in a volume of 0.5 ml. 
En peresnik odda en 30 mg ali 50 mg odmerek zdravila Eperzan v volumnu 0,5 ml. Velikost pakiranja:
On background therapy of metformin 1,500 mg daily, Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly after a minimum of 4 weeks) was compared to sitagliptin 100 mg daily, glimepiride 2 mg daily (with optional titration to 4 mg daily), or placebo. 
Na podlagi osnovnega zdravljenja z ≥ 1.500 mg metformina na dan so 30 mg zdravila Eperzan subkutano na teden (s fakultativnim zvišanjem na 50 mg na teden po najmanj 4 tednih) primerjali s 100 mg sitagliptina na dan, 2 mg glimepirida na dan (s fakultativnim titriranjem na 4 mg na dan) ali placebom.
Add-on to insulin glargine 
Dodatek insulinu glarginu
You should see the [2] in the number window (Figure G). 
V številčnem okencu morate videti [2] (Slika G).
Difference from placebo + met + glimb (95% CI) 
Razlika od kombinacije placebo + met + glimb (95 % IZ)
Patients may store the pens at room temperature, not exceeding 30C, for no more than a total of 4 weeks prior to use. 
Bolniki lahko peresnike shranjujejo na sobni temperaturi, ki ne presega 30 °C, a ne več kot skupaj 4 tedne pred uporabo.
Gastric motility 
Motiliteta želodca
3 Place pen into cup with clear cartridge pointing up (Figure I). 
3 Položite peresnik v posodico tako, da je prozorni vložek obrnjen navzgor (Slika I).
Common: may affect up to 1 in 10 people: 
Pogosti: pojavijo se lahko pri do 1 od 10 bolnikov:
The primary endpoint was change in HbA1c from baseline at 26 weeks. 
Primarni opazovani dogodek je bila sprememba HbA1c od izhodišča po 26 tednih.
If you stop using Eperzan, your blood sugar levels may be affected. 
Eperzan, to lahko vpliva na koncentracijo sladkorja v vaši krvi.
Results at 52 weeks in a placebo-controlled study comparing Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly) to pioglitazone 30 mg daily (with optional titration to 45 mg/day) as add-on therapy in patients inadequately controlled on metformin + sulphonylurea (glimepiride 4 mg daily) 
Rezultati (po 52 tednih) s placebom kontrolirane študije, ki je primerjala 30 mg zdravila Eperzan na teden subkutano (s fakultativnim zvišanjem na 50 mg na teden) s 30 mg pioglitazona na dan (s fakultativnim titriranjem na 45 mg/dan) kot dodatka zdravljenju bolnikov, neustrezno urejenih s kombinacijo metformin + sulfonilsečnina (glimepirid 4 mg na dan)
It may be necessary to reduce the dose of concomitantly administered insulin secretagogues (such as sulphonylureas) or insulin to reduce the risk of hypoglycaemia when starting Eperzan (see sections 4.4 and 4.8). 
Za zmanjšanje tveganja za hipoglikemijo po uvedbi zdravila Eperzan bi lahko bilo potrebno znižanje odmerka sočasno uporabljenih insulinskih sekretagogov (kot so sulfonilsečnine) ali insulina (glejte poglavji 4.4 in 4.8).
Multipack containing 12 single-dose pens and 12 pen needles (3 packs of 4 pens and 4 needles). 
Skupno pakiranje vsebuje 12 peresnikov z enkratnim odmerkom in 12 igel za peresnike (3 pakiranja s 4 peresniki in 4 iglami).
Results at 26 weeks in a study comparing Eperzan 30 mg SC weekly (with optional uptitration to 50 mg weekly) to prandial insulin lispro as add-on therapy in patients inadequately controlled on insulin glargine alone 
Rezultati (po 26 tednih) študije, ki je primerjala 30 mg zdravila Eperzan na teden subkutano (s fakultativnim zvišanjem na 50 mg na teden) s prandialnim insulinom lispro kot dodatkom zdravljenju bolnikov, neustrezno urejenih z insulinom glarginom samim
1.55 (1.05, 2.06) c a Intent to treat population - last observation carried forward b Adjusted mean c P<0.05 for treatment difference 
1,55 (1,05, 2,06) c a Populacija z-namenom-zdravljenja - prenos zadnjega opažanja b Korigirano povprečje c p < 0,05 za razliko med zdravljenji
Change at Week 52b Difference from placebob (95% CI) 
Sprememba po 52 tednihb Razlika od placebab (95 % IZ)
Eperzan 30 mg/50 mg Weekly + Metformin 1,500 mg daily + Glimepiride 4 mg daily 
Eperzan 30 mg/50 mg na teden + metformin ≥ 1.500 mg na dan + glimepirid 4 mg na dan
Difference from glimepiride + metforminb , (95% CI) a Intent to treat population - last observation carried forward b Adjusted mean c P<0.05 for treatment difference 
Razlika od kombinacije glimepirid + metforminb, (95 % IZ) a Populacija z-namenom-zdravljenja - prenos zadnjega opažanja b Korigirano povprečje c p < 0,05 za razliko med zdravljenji Dodatek pioglitazonu
Discard pen after use. 
Peresnik po uporabi zavrzite.
Immune system disorders 
Bolezni imunskega sistema preobčutljivo stna reakcija
Infections and infestations 
Infekcijske in parazitske bolezni pljučnica